On Wednesday, February 6th, FDA approved the Cablivi®(caplacizumab-yhdp) injection, the first product approved in combination with plasma exchange and immunosuppression specifically for adults with acquired thrombotic thrombocytopenic purpura (aTTP).
aTTP is the development of extensive blood clots in the small blood vessels throughout the body of a patient. These clots can cut off oxygen and blood supply to major organs and cause strokes and heart attacks that can lead to brain damage or death. The disorder can be developed in patients suffering from certain conditions such as cancer, HIV, pregnancy, lupus or infections, or after having surgery, a bone barrow transplant, or chemotherapy. An estimated 20% of patients die from aTTP episodes, with most deaths occurring within 30 days of diagnosis. In the United States it is reported that aTTP affects fewer than 2,000 adults each year.
In a recent statement, Dr. Richard Pazdur, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research stated that “patients with aTTP endure hours of treatment involving daily plasma exchange, which requires being attached to a machine that takes blood out of the body and mixes it with donated plasma and then returns it to the body.” In this release, Dr. Pazdur also points out that “even after days or weeks of this treatment, as well as taking drugs that suppress the immune system, many patients will have a recurrence of aTTP.”
The Cablivi injection was evaluated in the pivotal multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial known as HERCULES. The trial involved 145 patients who randomly received either Cablivi or a placebo, and all patients received the current standard care of plasma exchange and immunosuppressive therapy. The overall study period included the drug treatment period plus a 28-day follow up period after discontinuation of the treatment.
The results of the clinical trials displayed:
Common side effects that were reported by patients during the trials were nose bleeds (29%) or gingival (gums) bleeding (16%) and headache (21%). When administering Cablivi, health care providers are advised to monitor for bleeding in patients who currently take anticoagulants.
FDA granted Priority Review and Orphan Drug Designation to Ablynx for Cablivi, which provides incentives to assist and encourage the development of drugs for rare diseases. Cablivi is expected to be available in the United States late in the first quarter of 2019.
March 7, 2017
On Monday, March 6th, the FDA announced plans to hold a public meeting regarding the development of patient-focused drugs for autism. In the notice published in the Federal Register, the FDA notes...
September 13, 2018
On Thursday, September 6th, the FDA released a new draft guidance regarding benefit-risk determinations in medical device premarket approval applications (PMAs), De Novo requests, and humanitarian...